Genomic Reports Initial Results From TAILORx In Breast Cancer

(RTTNews) - Genomic Health Inc. (GHDX) Monday announced initial results from the Trial Assigning IndividuaLized Options for Treatment or Rx, or TAILORx. The study demonstrated that a group of trial participants with low 21-gene recurrence score (Oncotype DX Recurrence Score) results of 10 or less who received hormonal therapy alone without chemotherapy had less than a one percent chance of distant recurrence at five years.

TAILORx is a multi-center prospectively conducted trial of over 10,000 women with early stage breast cancer sponsored by the National Cancer Institute, and led by the ECOG-ACRIN Cancer Research Group with support from Genomic Health.

This finding was published online today by the New England Journal of Medicine. It provides evidence that other women in the future may effectively use hormonal therapy alone if the Recurrence Score is 10 or less.

Second primary cancers exceeded recurrences of the original breast cancer, resulting in 93.8 percent five year disease free survival, which was the primary trial endpoint.

These results, also presented at the 2015 European Cancer Congress today, involve the group of 1,626 patients with a Recurrence Score between 0 and 10.

It demonstrated that 99.3 percent of patients who met accepted guidelines for recommending chemotherapy in addition to hormonal therapy, had no distant recurrence at five years after treatment with hormonal therapy alone.

The patients were node-negative, estrogen receptor-positive, human epidermal growth factor receptor 2 -negative.

Outcomes were excellent irrespective of patient age at diagnosis, tumor size, and tumor grade, the company noted.